中国肺癌杂志2025，Vol.28Issue(4)：245-255,11.DOI:10.3779/j.issn.1009-3419.2025.106.10
肺癌小分子靶向药物临床合理用药专家共识
Expert Consensus on Rational Use and Monitoring of Small Molecule Targeted Drugs for Lung Cancer
赵丽岩 1唐可京 1《肺癌小分子靶向药物临床合理用药专家共识》工作组 1广东省女医师协会肺癌专业委员会1
作者信息
摘要
Abstract
The application of small molecule targeted drugs for lung cancer has significantly improved the survival of lung cancer patients.However,these drugs have a wide variety of types,fast development and market launch of new drugs,complex adverse reactions,and are mostly used at home,which increases the risk of irrational drug use.At the same time,insuf-ficient monitoring of efficacy and safety is also prone to occur,ultimately affecting treatment outcomes.This consensus focuses on 43 small molecule targeted drugs or combinations for lung cancer,providing standardized recommendations for rational drug use and monitoring of efficacy/adverse reactions in clinical practice.The recommendations are regarding drug selection,dosage adjustment,efficacy monitoring,adverse reaction monitoring,and improvement of patient compliance.This consensus aims to improve the rational use and efficacy/safety monitoring quality of small molecule targeted drugs for lung cancer,ensure the effectiveness and safety of drug treatment,prolong the survival of lung cancer patients and improve their quality of life.关键词
肺肿瘤/小分子靶向药物/合理用药/疗效监测/不良反应监测Key words
Lung neoplasms/Small molecule targeted therapeutic drugs/Rational use of drugs/Efficacy monitoring/Adverse drug reaction monitoring引用本文复制引用
赵丽岩,唐可京,《肺癌小分子靶向药物临床合理用药专家共识》工作组,广东省女医师协会肺癌专业委员会..肺癌小分子靶向药物临床合理用药专家共识[J].中国肺癌杂志,2025,28(4):245-255,11.
